These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23570177)

  • 1. SOP 01: Clinical investigations in CESAR.
    Onkologie; 2003 Oct; 26 Suppl 6():1-4. PubMed ID: 23570177
    [No Abstract]   [Full Text] [Related]  

  • 2. SOP 02: Evaluation and selection of a clinical trial proposal for CESAR.
    Onkologie; 2003 Oct; 26 Suppl 6():5-10. PubMed ID: 23570178
    [No Abstract]   [Full Text] [Related]  

  • 3. SOP 07a: Monitoring of a trial under CESAR responsibility.
    Onkologie; 2003 Oct; 26 Suppl 6():38-40. PubMed ID: 23570184
    [No Abstract]   [Full Text] [Related]  

  • 4. SOP 06: Selecting the participating centers and activation of a trial.
    Onkologie; 2003 Oct; 26 Suppl 6():34-5. PubMed ID: 23570182
    [No Abstract]   [Full Text] [Related]  

  • 5. SOP 10: Study report and publication.
    Onkologie; 2003 Oct; 26 Suppl 6():48-9. PubMed ID: 23570187
    [No Abstract]   [Full Text] [Related]  

  • 6. SOP 03: Preparation and structure of trial protocols.
    Onkologie; 2003 Oct; 26 Suppl 6():11-4. PubMed ID: 23570179
    [No Abstract]   [Full Text] [Related]  

  • 7. SOP 04: Data collection forms (case report forms).
    Onkologie; 2003 Oct; 26 Suppl 6():15-22. PubMed ID: 23570180
    [No Abstract]   [Full Text] [Related]  

  • 8. SOP 07: Data flow, monitoring, and archiving.
    Onkologie; 2003 Oct; 26 Suppl 6():36-7. PubMed ID: 23570183
    [No Abstract]   [Full Text] [Related]  

  • 9. Standard Operating Procedures for clinical trials of the CESAR Central European Society for Anticancer Drug Research--EWIV. Preface.
    Gastl G; Dittrich C
    Onkologie; 2003 Oct; 26 Suppl 6():IX. PubMed ID: 23570176
    [No Abstract]   [Full Text] [Related]  

  • 10. SOP 12: Validation of bioanalytical methods.
    Onkologie; 2003 Oct; 26 Suppl 6():52-5. PubMed ID: 23570189
    [No Abstract]   [Full Text] [Related]  

  • 11. [Preclinical data as basis for the design of clinical studies].
    Fichtner I
    Onkologie; 2008; 31 Suppl 2():34-8. PubMed ID: 18487867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOP 08: Reporting of adverse events.
    Onkologie; 2003 Oct; 26 Suppl 6():41-2. PubMed ID: 23570185
    [No Abstract]   [Full Text] [Related]  

  • 13. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

  • 14. SOP 13: Pharmacokinetic data analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():56-9. PubMed ID: 23570190
    [No Abstract]   [Full Text] [Related]  

  • 15. SOP 05: Patient information and informed consent.
    Onkologie; 2003 Oct; 26 Suppl 6():23-33. PubMed ID: 23570181
    [No Abstract]   [Full Text] [Related]  

  • 16. The pharmaceutical industry and oncology in central and eastern Europe.
    Ben-Am M; Gemperli B; Covelli A; Burke G
    Ann Oncol; 1999; 10 Suppl 6():15-7. PubMed ID: 10676548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOP 14: Population pharmacokinetic analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():60-6. PubMed ID: 23570191
    [No Abstract]   [Full Text] [Related]  

  • 18. Legal considerations in clinical cancer research.
    Robertson JA
    Semin Oncol; 1981 Dec; 8(4):442-6. PubMed ID: 7323817
    [No Abstract]   [Full Text] [Related]  

  • 19. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML; Carbone DP; Johnson DH
    Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
    Leighton JK; Saber H; Reaman G; Pazdur R
    Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.